Part or Boehringer’s broader clinical program targeting diabetic retinal disease, BI 1815368 is the fourth investigational compound from Boehringer Ingelheim’s Eye Health portfolio to advance to a ...

At the 2025 Annual Meeting, I had the privilege of 1 I have been working on over the past year—exploring how retinal imaging might help detect early signs of Alzheimer disease (AD), especially in ...